Piramal Pharma Solutions and NP2 Near Completion of Critical Cyclophosphamide Development Program
LEXINGTON, Ky. — In a significant move to stabilize the U.S. oncology supply chain, global Contract Development and Manufacturing Organization (CDMO) Piramal Pharma Solutions (PPS) and the nonprofit drug manufacturer NP2 have announced that they are on track to finalize the development phase of the generic cancer drug cyclophosphamide this October.
Cyclophosphamide is a vital, sterile injectable medicine utilized in the treatment of various malignancies, including breast cancer and retinoblastoma, a rare form of eye cancer primarily affecting young children. Despite its status as a frontline therapy, the drug has faced chronic supply chain disruptions across North America, leading to alarming shortages that have hindered patient care in the U.S., Canada, and Europe.
To address these vulnerabilities, NP2 has partnered with PPS to utilize its Lexington, Kentucky, facility for both the development and future manufacturing of the drug. By consolidating the development and production processes within the United States, the collaboration aims to drastically shorten the supply chain, moving the finished product from the factory floor to the clinic with greater speed and efficiency.
The initiative comes at a time when the Lexington site is already undergoing a major $85 million expansion. This capital investment is designed to scale up manufacturing capacity, ensuring that facilities are equipped to handle the high-volume production of essential oncology therapies like cyclophosphamide.
“What we’re seeing with the cyclophosphamide shortages in the EU and Canada is clearly alarming,” said Terri Miller, Executive Director of NP2. “A reliable U.S.-made supply of cyclophosphamide—a mainstay cancer-fighting medicine—does not exist today. NP2 is building it. We believe patients should be able to focus on fighting their cancer, not fretting about the availability of a life-saving drug they urgently need. That’s what motivates us to move forward.”
The partnership represents a broader shift toward domestic pharmaceutical self-sufficiency. By leveraging PPS’s global manufacturing expertise and NP2’s mission-driven approach to drug production, the collaboration seeks to eliminate the reliance on volatile international supply lines that have exacerbated shortages in recent years.
“We are proud to partner with NP2 on this important initiative to strengthen the supply of critical oncology medicines for patients in the United States,” said Peter DeYoung, CEO of Piramal Global Pharma. “With the ongoing expansion of our Lexington facility, we are building a more resilient domestic supply chain and helping to support reliable access to this essential cancer therapy.”
As the project moves into the final stages of its development phase this October, the collaboration stands as a critical milestone for cancer patients across the country, promising a more dependable path to treatment for those who need it most.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
